Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Cluster of Differentiation 47 (CD47)
100%
Anticancer Immunity
100%
4-1BB
100%
Rituximab
83%
Diffuse Large B-cell Lymphoma (DLBCL)
83%
Lymphoma Patients
50%
Macrophages
50%
Cancer Cells
50%
Lymphoma Cells
33%
Costimulatory Molecules
33%
Patient-derived
33%
Cynomolgus Monkey
33%
Polymorphonuclear Neutrophils
33%
T Cell Cytotoxicity
33%
T Cells
16%
Immune Cells
16%
Healthy Donors
16%
B-cell Lymphoma
16%
Activated T Cells
16%
Monoclonal Antibody
16%
Therapeutic Use
16%
Cell number
16%
Treatment Regimen
16%
T Cell Immunity
16%
Mixed Culture
16%
Xenograft
16%
Fusion Protein
16%
Phagocytosis
16%
Extracellular Domain
16%
T Cell Activation
16%
Safety Profile
16%
Relapsed or Refractory
16%
Cell Co-culture
16%
Specific Binding
16%
Phagocytes
16%
Anticancer Immune Response
16%
Tumor Size
16%
Anticancer
16%
Anticancer Activity
16%
Phase I Trial
16%
Prolonged Treatment
16%
Cytotoxicity Assay
16%
Acquired Resistance
16%
Diffuse Large B-cell Lymphoma Cells
16%
Neutrophil Cells
16%
Intrinsic Resistance
16%
Signaling Axis
16%
Ratio-dependent
16%
Objective Response Rate
16%
Reporter Cells
16%
Cytotoxicity in Vitro
16%
Tumor-infiltrating T Cells
16%
Refractory Diffuse Large B-cell Lymphoma
16%
Phagocytosis Assay
16%
Xenograft Mouse Model
16%
Human PBMCs
16%
Trogocytosis
16%
4-1BBL
16%
Fully Human
16%
Bispecific
16%
Immunology and Microbiology
B Cell
100%
CD47
100%
Rituximab
83%
T Cell
66%
Macrophage
50%
Cancer Cell
50%
Cytotoxicity
33%
Neutrophil Granulocyte
33%
Phagocytosis
33%
Xenograft
33%
Macaca fascicularis
33%
In Vitro
33%
Mouse Model
16%
Adoptive Immunity
16%
Mixed Cell Culture
16%
Immunocompetent Cell
16%
Immune Response
16%
Coculture
16%
Monoclonal Antibody
16%
T Cell Activation
16%
Phagocyte
16%
Tumor Volume
16%
Antineoplastic Activity
16%
Diffuse Large B-Cell Lymphoma Cell Line
16%
Tumor Necrosis Factor Receptor Superfamily Member 9
16%
B-Cell Lymphoma Cell Line
16%
Trogocytosis
16%
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
Rituximab
83%
T Cell
66%
Cancer Cell
50%
Macrophage
50%
Neoplasm
33%
In Vitro
33%
Xenograft
33%
Phagocytosis
33%
Neutrophil
33%
Monoclonal Antibody
16%
Cellular Immunity
16%
Cytotoxicity
16%
Immunocompetent Cell
16%
Immune Response
16%
Chimeric Protein
16%
T Cell Activation
16%
Antineoplastic Activity
16%
CHOP
16%
Cytotoxicity Assay
16%
Phase I Trials
16%
B-Cell Lymphoma Cell Line
16%
Tumor Necrosis Factor Receptor Superfamily Member 9
16%
Diffuse Large B-Cell Lymphoma Cell Line
16%
Haplorhini
16%
Therapeutic Use
16%